Cureverse
PrivateLast Round
Private Equity
Oct 1, 2026
Est. Valuation
$47.47M
Total Funding Raised
$27.5M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Cureverse operates in Healthcare & Life Sciences and is based in Seoul. Its latest recorded funding round was a Series B round in January 2025.
Cureverse is a biotechnology company that develops small-molecule drugs for the treatment of neurodegenerative diseases, cancer, and inflammatory disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cureverse Comparables
Compare Cureverse with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Merry Life Biomedical Company, Ltd. | 83% | |
| Brenig Therapeutics | 80% | |
| Neuracle Science | 80% |
For institutional investors. Book with your work email.
Cureverse Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Equity | Oct 1, 2026 | ||||
| Series B | Jan 1, 2025 | ||||
| Series A | May 1, 2022 | ||||
| Pre Seed | Oct 1, 2021 |
For institutional investors. Book with your work email.
Cureverse Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BNH INVESTMENT | Private Equity |
| Ministry of Science and ICT of South Korea | Pre Seed |
| KB Securities | Series B |
| IBK Venture Investment | Private Equity |
| Yuanta Investment | Series B, Series A |
| Daekyo Investment | Series B, Series A |
| Ministry of Health and Welfare (South Korea) | Pre Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2026
$17.1M round with IBK Venture Investment and BNH INVESTMENT.
- Sep 12, 2026
Monthly visitors increased 70% MoM.
For institutional investors. Book with your work email.
Cureverse Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Cureverse's valuation, stock price, and market status.
Is Cureverse a public or private company?
Cureverse is a private company.
What is the current stock price of Cureverse?
Cureverse is a private company, so its shares have no public market price. Caplight tracks Cureverse's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cureverse worth (valuation)?
Cureverse's valuation is estimated at $47.5M based on funding round data.
Can I buy Cureverse stock?
Cureverse shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cureverse's last funding round?
Cureverse's most recent funding round was Private Equity on October 1, 2026.
Who are the main investors in Cureverse?
Key investors in Cureverse include STIC Ventures.
Will Cureverse IPO soon?
No public IPO plans have been announced for Cureverse.
How can I track Cureverse secondary market activity?
Caplight tracks bids, offers, and trades in Cureverse's shares on secondary markets.